Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an immunosuppressant presented as a delayed‑release tablet for oral use. It is indicated to prevent organ rejection in kidney and other solid organ transplant recipients, helping maintain graft function.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, providing quality‑assured products sourced from EU‑authorized manufacturers. The company adheres to stringent regulatory standards and offers reliable logistics for global markets, benefiting clients with transparent pricing, batch traceability, and dedicated technical support throughout the supply chain.

Myfortic (mycophenolate sodium) is used in the immunosuppressive pathway to prevent graft rejection after solid organ transplantation.

Kidney transplant: prevents acute and chronic rejection, supporting long‑term graft survival. Liver transplant: reduces risk of rejection and improves graft function. Heart transplant: helps maintain graft tolerance and reduces incidence of rejection episodes.

Myfortic may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: anemia, leukopenia, or thrombocytopenia. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as cytomegalovirus or Pneumocystis jirovecii pneumonia. - Neurotoxicity: seizures, encephalopathy, or posterior reversible encephalopathy syndrome. - Malignancy: increased risk of lymphoproliferative disorders or skin cancers.

When prescribing Myfortic, clinicians should consider several precautionary measures to minimize risk. - Renal function: adjust use in patients with impaired renal clearance. - Hepatic function: monitor liver enzymes as the prodrug is metabolized in the liver. - Infection risk: screen for latent infections and vaccinate before initiation. - Pregnancy: category D; avoid use unless benefits outweigh risks. - Contraception: advise women of child‑bearing potential to use effective contraception. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Myfortic interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of mycophenolate; separate dosing by at least 2 hours. - Cyclosporine or tacrolimus: increase mycophenolate exposure and risk of hematologic toxicity.

Moderate Interactions (Monitor Closely): - Vaccines: live attenuated vaccines may cause infection; avoid during therapy. - Azathioprine: additive bone marrow suppression; monitor blood counts. - Contraceptive hormones: may reduce efficacy; consider alternative methods.